NAACCR June 2010 The System Performance Initiative: A Pan-Canadian Approach 1.

Slides:

Advertisements

Similar presentations

This grey area will not appear in your presentation. Fighting back Against Colon Cancer Presentations prepared by: Canadian Cancer Society, Ontario Division,

Advertisements

Advances and Emerging Therapy for Lung Cancer

National Oesophago–Gastric Cancer Audit Comparing local and national figures.

Canadian Cancer Risk Management Model: A new health policy tool useful in policy decisions related to lung cancer WK Evans, M Wolfson, WM Flanagan, J Oderkirk,

Breast Cancer Reimbursement Policy in Taiwan Mao-Ting Sheen Director Bureau of National Health Insurance Department of Health, Executive Yuan November.

4.6 Assessment of Evaluation and Treatment 2013 Analytic Lung Cancer.

Clinical Solutions for Lung Cancer Screening (LCS)

April 6, o What is cancer? o Cancer statistics o Cancer prevention and early detection o Cancer disparities o Cancer survivorship o Cancer research.

Cancer Statistics 2013 A Presentation from the American Cancer Society

Radiation Therapy as an Effective Tool to fight cancer in Women: Future Trends R. Sankaranarayanan MD Screening Group International Agency for Research.

1 Measuring health care quality at the international level: Introduction to the OECD Health Care Quality Indicators Project Peter Scherer Head, Health.

Andrea Janeš Mentor: A. Žmegač Horvat

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Cancer Program Fewer Montanans experience late stage cancer. Fewer Montanans die of cancer. Metrics Biannual percent of Montanans who are up-to-date with.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.

Breast Cancer Detection, Treatment, and Survival in Medicare and Medicaid Insured Patients Cathy J. Bradley, Ph.D. Professor of Health Administration Co-leader,

Derek Martinig Suzanne Lane Julia Barnscher.  FDG (18-fluoro-2-deoxyglucose) – Radioactive F in place of O in glucose  Fluoride decays back to Oxygen.

Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

A cancerous cell is caused by a faulty reproduction system. The cell continues to reproduce at a very fast rate When cells reproduce at an abnormally.

Colon Cancer First Page.

Lung Cancer Emily Cauchon Katie Reeves Emily Cauchon Katie Reeves.

Cancer Care Ontario A Organizational Overview S Orientation Workshop July 16, 2014 Sheila M Densham, BA, TEACH Health Promotion Coordinator.

Beyond Standard Adjuvant Therapy for Colon Cancer: Role of Nonstandard Interventions Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA.

COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.

Breast Cancer: Treatment or Not? HFE 742 Cathy Simmons November 10, 2005.

Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

(4) Radiation Therapy Oncology Group (RTOG)

EUNICE Breast Screening Monitoring User guide

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

TOWARD AN INVENTORY OF RISK FACTORS ASSOCIATED WITH CHRONIC CONDITIONS Presentation to the Association of Public Health Epidemiologists of Ontario [APHEO]

Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.

Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

National Conference on Tobacco or Health December 2003 Changing the System Smoking Cessation Supports for Hospital Patients and Staff Christina Krause.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

Cancer Committee Meeting May 11, 2015 Cancer Liaison Physician Report Karen Lisa Smith MD MPH.

Interventions for Clients with Colorectal Cancer.

Human Biology Presentation Guidance February 2015.

Using SEER-Medicare Data to Enhance Registry Data to Assess Quality of Care Joan Warren Applied Research Program National Cancer Institute NAACCR June.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

The Cancer Registry of Norway Jan F Nygård Head of the IT-department.

THE NEW WORLD OF STANDARDIZED ELECTRONIC PATHOLOGY (E-PATH) REPORTING Eric B. Durbin, MS Jovanka N. Harrison, PhD NAACCR Pathology Data Work Group NAACCR.

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,

Cancer System Quality Index (CSQI) 2012 Treatment.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Adult Social Care and Health Select Committee Cancer in Nottingham Julie O’Boyle Specialty Registrar Public Health NHS Nottingham City Dr Chris Packham.

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Cervical Cancer Tiffany Smith HCP 102.

#BlackHealthMatters: Improving Breast Cancer Outcomes for Black Women

Oesophago–Gastric Cancer Audit

SWAG SSG Upper GI Cancer Meeting

تهیه کننده: استاد مربوطه: بهار 1392

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Review – First Exam Chapters 1 through 5

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Effect of Obesity on Prognosis after Early Breast Cancer

Standard 3.1 Patient Navigation Process

Yang Zhang, MD, Haiquan Chen, MD, PhD

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

General strategies of Cancer Treatment and evaluation of Response

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Presentation transcript:

NAACCR June 2010 The System Performance Initiative: A Pan-Canadian Approach 1

The International Landscape… 3 European Cancer Health Indicator Project Cancer System Quality Index (CSQI) 2009

4 First System Performance Report (2009): Process for Indicator Selection 4

5 First System Performance Report (2009) Thanks to the System Performance Steering Committee Dr. Ivo OlivottoBC Dr. Peter CraigheadAB Mr. Ivan OlfertSK Dr. Brent SchacterMB Ms. Helen AngusON Dr. Denis RoyQC Dr. Grlica BolesnikovNB Dr. Margaret FitchON 5

Examples of Indicator Selection Criteria Coverage of cancer control continuum Reflective of outcomes, not process alone Impact on total cancer population Measurable Available (combination of this and “stretch goals” for measurement) Known directionality…..

7 Indicators First Report (2009) 7

An iterative process..... Over first year, no intention to build ‘targets.’ Goal was to develop a process of sharing that would generate hypotheses and begin to identify reporting priorities The Report will develop further as confidence in the process and quality of information increases……. Analysis 2009: We presented national data, provincial comparisons, and data trends over time We also reported on SES, Education and Urban/Rural status where possible 8

The System Performance Initiative – A First Year Report

Smoking Prevalence & Smoking Quit Attempts – Canada (CCHS) 10

Smoking Quit Attempts over time and by Age Group – Canada (CCHS)

A pan-Canadian approach……. Using the data Example: Overweight & Obesity

A pan-Canadian approach……. Using the data Example: Overweight & Obesity

– Second SP Report…… and beyond Winter Feasibility Study for new indicators JanuaryData ask to provinces CurrentData analysis and refinement JulyEmbargoed release of “Overview” Report Jul – AugFeedback & Clarification SeptemberYear 2 Report published 2 subsequent drill-down reports expected (Fall 2010, Spring 2011) 14

15 Pan-Canadian System Performance Working Group First conference call – November 2009 Dr. Susan O’ReillyBC Dr. Peter CraigheadAB Mr. Ivan OlfertSK Dr. Eric BowMB Ms. Katya DuvalkoON TBAQC Dr. Grlica BolesnikovNB Mr. Gordon WalshNS Dr. Dagny DryerPEI Ms. Sharon SmithNL 15

16 And report on: 11 Proposed New Indicators 16 Guideline Concordance Indicators Other Adjuvant chemotherapy for fully resected Stage III colon cancer Removal & examination of 12 or more lymph nodes for colon cancer Adjuvant radiation therapy following breast conserving surgery for Stage I & II breast cancer Neoadjuvant radiation therapy for Stage II and III rectum cancer (Palliative) Site of Cancer Death Clinical Trial Participation Rates HPV Vaccination Rates (school-based programs) Systemic Therapy Utilization Rates Wait Times, FOBT to Colonoscopy Patient Reported Outcomes Adjuvant chemotherapy for fully resected Stage II & IIIA Non-Small Cell Lung Cancer

Thank you! The 2009 Report is available online at: For more information, please contact: Mary Spayne, Director, System Performance